CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer

Table 2

Correlation between the number of CD68⁺ or CD163⁺ macrophages and relevant clinical characteristics of the EC cases.

Parameters	Patients ()	Patients (%)	CD68^+ macrophages		CD163^+ macrophages
			Mean ± SEM	value	Mean ± SEM	value
Total age (year)	47	100
<55	16	34.0	63.37 ± 6.261	0.9676	62.44 ± 6.602	0.7301
≥55	31	66.0	63.73 ± 5.684		58.95 ± 6.336
Grade (endometrioid = 37)	37
G1 or G2	33	88.6	63.45 ± 5.344	0.1247	56.40 ± 4.675	0.0118^a
G3	4	11.4	88.98 ± 15.07		99.65 ± 29.49
FIGO stage
I or II	26	55.3	51.19 ± 5.009	0.0007^a	44.71 ± 3.859	< 0.0001^a
III or IV	21	44.7	78.83 ± 5.731		79.24 ± 7.620
Histologic type
Endometrioid	37	78.7	65.04 ± 4.977	0.507	60.65 ± 5.361	0.8364
Nonendometrioid	10	21.3	57.98 ± 7.415		58.24 ± 10.32
Myometrial invasion
<1/2	31	66	62.04 ± 5.638	0.6016	58.05 ± 5.843	0.5433
≥1/2	16	34	66.81 ± 5.857		64.18 ± 8.107
Positive lymph nodes
No	33	64.1	54.75 ± 5.356	0.0042^a	47.87 ± 4.430	0.0008^a
Yes	14	35.9	81.63 ± 6.996		84.15 ± 10.81
Lymphovascular space involvement
No	25	53.2	52.27 ± 5.558	0.0033^a	47.48 ± 4.536	0.0031^a
Yes	22	46.8	76.40 ± 5.419		74.53 ± 7.646

^a, the difference between CD68/CD163 expression in patients and different grades, FIGO stages, with or without lymph node metastasis, or lymphovascular space involvement.